Detalhe da pesquisa
1.
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Cancer Immunol Immunother
; 73(7): 119, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713205
2.
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
Eur J Cancer
; 199: 113539, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38237373
3.
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.
Nat Med
; 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38824242
4.
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Eur J Cancer
; 181: 26-37, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36628898
5.
Effectiveness and complication rates of tension-free vaginal tape, transobturator tape, and tension-free vaginal tape-obturator in the treatment of female stress urinary incontinence in a medium- to long-term follow up. Meta-analysis of randomized controlled trials.
Saudi Med J
; 35(1): 20-32, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24445886